Effects of once-weekly semaglutide on appetite, energy intake, control of eating, food preference and body weight in subjects with obesity

John Blundell, Graham Finlayson, Mads Axelsen, Anne Flint, Catherine Gibbons, Trine Kvist, Julie B Hjerpsted, John Blundell, Graham Finlayson, Mads Axelsen, Anne Flint, Catherine Gibbons, Trine Kvist, Julie B Hjerpsted

Abstract

Aim: The aim of this trial was to investigate the mechanism of action for body weight loss with semaglutide.

Materials and methods: This randomised, double-blind, placebo-controlled, two-period crossover trial investigated the effects of 12 weeks of treatment with once-weekly subcutaneous semaglutide, dose-escalated to 1.0 mg, in 30 subjects with obesity. Ad libitum energy intake, ratings of appetite, thirst, nausea and well-being, control of eating, food preference, resting metabolic rate, body weight and body composition were assessed.

Results: After a standardised breakfast, semaglutide, compared with placebo, led to a lower ad libitum energy intake during lunch (-1255 kJ; P < .0001) and during the subsequent evening meal ( P = .0401) and snacks ( P = .0034), resulting in a 24% reduction in total energy intake across all ad libitum meals throughout the day (-3036 kJ; P < .0001). Fasting overall appetite suppression scores were improved with semaglutide vs placebo, while nausea ratings were similar. Semaglutide was associated with less hunger and food cravings, better control of eating and a lower preference for high-fat foods. Resting metabolic rate, adjusted for lean body mass, did not differ between treatments. Semaglutide led to a reduction from baseline in mean body weight of 5.0 kg, predominantly from body fat mass.

Conclusion: After 12 weeks of treatment, ad libitum energy intake was substantially lower with semaglutide vs placebo with a corresponding loss of body weight observed with semaglutide. In addition to reduced energy intake, likely mechanisms for semaglutide-induced weight loss included less appetite and food cravings, better control of eating and lower relative preference for fatty, energy-dense foods.

Keywords: Body composition; Energy regulation; GLP-1 analogue; Glucagon-like peptide-1; Randomised trial; Semaglutide; Type 2 diabetes; Visual analogue scale.

© 2017 The Authors. Diabetes, Obesity and Metabolism published by John Wiley & Sons Ltd.

Figures

Figure 1
Figure 1
Energy intake during A, ad libitum meals and B, ad libitum snack box, by food group. Abbreviations: CI, confidence interval; ETD, estimated treatment difference. Relative difference: ETD / estimated mean for placebo × 100%.
Figure 2
Figure 2
A, Overall appetite suppression score during the standardised breakfast; B, visual analogue scale (VAS) ratings of appetite during a standardised breakfast and C, fasting VAS ratings. Abbreviations: CI, confidence interval; ETD, estimated treatment difference. Overall appetite suppression score = (satiety + fullness + [100 − hunger] + [100 − prospective food consumption]) / 4. 100 indicates less appetite; 0 indicates more appetite. Error bars represent 95% CI.
Figure 3
Figure 3
Results of the Control of Eating Questionnaire (COEQ). Abbreviations: CI, confidence interval; ETD, estimated treatment difference. Results for the open‐ended question “Which one food makes it difficult for you to control eating?” (question 15) not shown. Error bars represent 95% CI.
Figure 4
Figure 4
A, Absolute mean body weight change and B, estimated mean change in body composition. Body weight and body composition were measured on distinct days. Error bars represent standard error of the mean.

References

    1. Kieffer TJ, Habener JF. The glucagon‐like peptides. Endocr Rev. 1999;20:876‐913.
    1. Donath MY, Burcelin R. GLP‐1 effects on islets: hormonal, neuronal, or paracrine? Diabetes Care. 2013;36(suppl 2):S145‐S148.
    1. Flint A, Raben A, Astrup A, Holst JJ. Glucagon‐like peptide 1 promotes satiety and suppresses energy intake in humans. J Clin Invest. 1998;101:515‐520.
    1. Gutzwiller JP, Drewe J, Goke B, et al. Glucagon‐like peptide‐1 promotes satiety and reduces food intake in patients with diabetes mellitus type 2. Am J Physiol. 1999;276:R1541‐R1544.
    1. Dickson SL, Shirazi RH, Hansson C, Bergquist F, Nissbrandt H, Skibicka KP. The glucagon‐like peptide 1 (GLP‐1) analogue, exendin‐4, decreases the rewarding value of food: a new role for mesolimbic GLP‐1 receptors. J Neurosci. 2012;32:4812‐4820.
    1. Nauck M, Frid A, Hermansen K, et al. Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)‐2 study. Diabetes Care. 2009;32:84‐90.
    1. Marre M, Shaw J, Brandle M, et al. Liraglutide, a once‐daily human GLP‐1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD‐1 SU). Diabet Med. 2009;26:268‐278.
    1. Van Gaal L, Scheen A. Weight management in type 2 diabetes: current and emerging approaches to treatment. Diabetes Care. 2015;38:1161‐1172.
    1. Pi‐Sunyer X, Astrup A, Fujioka K, et al. A randomized, controlled trial of 3.0 mg of liraglutide in weight management. N Engl J Med. 2015;373:11‐22.
    1. van Can J, Sloth B, Jensen CB, Flint A, Blaak EE, Saris WH. Effects of the once‐daily GLP‐1 analog liraglutide on gastric emptying, glycemic parameters, appetite and energy metabolism in obese, non‐diabetic adults. Int J Obes (Lond). 2014;38:784‐793.
    1. van Bloemendaal L, IJzerman RG, Ten Kulve JS, et al. GLP‐1 receptor activation modulates appetite‐ and reward‐related brain areas in humans. Diabetes. 2014;63:4186‐4196.
    1. Sisley S, Gutierrez‐Aguilar R, Scott M, D'Alessio DA, Sandoval DA, Seeley RJ. Neuronal GLP1R mediates liraglutide's anorectic but not glucose‐lowering effect. J Clin Invest. 2014;124:2456‐2463.
    1. Lau J, Bloch P, Schaffer L, et al. Discovery of the once‐weekly glucagon‐like peptide‐1 (GLP‐1) analogue semaglutide. J Med Chem. 2015;58:7370‐7380.
    1. Kapitza C, Nosek L, Jensen L, Hartvig H, Jensen CB, Flint A. Semaglutide, a once‐weekly human GLP‐1 analog, does not reduce the bioavailability of the combined oral contraceptive, ethinylestradiol/levonorgestrel. J Clin Pharmacol. 2015;55:497‐504.
    1. Marbury T, Flint A, Segel S, Lindegaard M, Lasseter K. Pharmacokinetics and tolerability of a single dose of semaglutide, a once‐weekly human GLP‐1 analogue, in subjects with and without renal impairment. Diabetologia. 2014;57(suppl 1):S358.
    1. Saini SD, Schoenfeld P, Kaulback K, Dubinsky MC. Effect of medication dosing frequency on adherence in chronic diseases. Am J Manag Care. 2009;15:e22‐e33.
    1. Polonsky WH, Fisher L, Hessler D, Bruhn D, Best JH. Patient perspectives on once‐weekly medications for diabetes. Diabetes Obes Metab. 2011;13:144‐149.
    1. Madsbad S, Kielgast U, Asmar M, Deacon CF, Torekov SS, Holst JJ. An overview of once‐weekly glucagon‐like peptide‐1 receptor agonists–available efficacy and safety data and perspectives for the future. Diabetes Obes Metab. 2011;13:394‐407.
    1. Nauck MA, Petrie JR, Sesti G, et al. A phase 2, randomized, dose‐finding study of the novel once‐weekly human GLP‐1 analog, semaglutide, compared with placebo and open‐label liraglutide in patients with type 2 diabetes. Diabetes Care. 2016;39:231‐241.
    1. European Agency for the Evaluation of Medicinal Products . International Conference on Harmonisation‐World Health Organization Guideline for Good Clinical Practice [EMEA Web site] ICH Harmonised tripartite guideline good clinical practice . . Accessed January 11, 2016.
    1. World Medical Association . Declaration of Helsinki ethical principles for medical research involving human subjects. 52nd WMA General Assembly; October 2000; Edinburgh, Scotland: Last amended with Note of Clarification on Paragraph 29 by the WMA General Assembly; Washington, 2002; and Note of Clarification on Paragraph 30 by the WMA General Assembly; Tokyo, 2004. . Accessed January 14, 2016.
    1. Flint A, Raben A, Blundell JE, Astrup A. Reproducibility, power and validity of visual analogue scales in assessment of appetite sensations in single test meal studies. Int J Obes Relat Metab Disord. 2000;24:38‐48.
    1. Nicholson MJ, Holton J, Bradley AP, Beatty PC, Campbell IT. The performance of a variable‐flow indirect calorimeter. Physiol Meas. 1996;17:43‐55.
    1. Hill AJ, Weaver CF, Blundell JE. Food craving, dietary restraint and mood. Appetite. 1991;17:187‐197.
    1. Dalton M, Finlayson G, Hill A, Blundell J. Preliminary validation and principal components analysis of the Control of Eating Questionnaire (CoEQ) for the experience of food craving. Eur J Clin Nutr. 2015;69:1313‐1317.
    1. Finlayson G, King N, Blundell J. The role of implicit wanting in relation to explicit liking and wanting for food: implications for appetite control. Appetite. 2008;50:120‐127.
    1. Finlayson G, Bordes I, Griffioen‐Roose S, de Graaf C, Blundell JE. Susceptibility to overeating affects the impact of savory or sweet drinks on satiation, reward, and food intake in nonobese women. J Nutr. 2012;142:125‐130.
    1. Finlayson G, Arlotti A, Dalton M, King N, Blundell JE. Implicit wanting and explicit liking are markers for trait binge eating. A susceptible phenotype for overeating. Appetite. 2011;57:722‐728.
    1. Verschoor E, Finlayson G, Blundell J, Markus CR, King NA. Effects of an acute alpha‐lactalbumin manipulation on mood and food hedonics in high‐ and low‐trait anxiety individuals. Br J Nutr. 2010;104:595‐602.
    1. Griffioen‐Roose S, Finlayson G, Mars M, Blundell JE, de Graaf C. Measuring food reward and the transfer effect of sensory specific satiety. Appetite. 2010;55:648‐655.
    1. Fields DA, Goran MI, McCrory MA. Body‐composition assessment via air‐displacement plethysmography in adults and children: a review. Am J Clin Nutr. 2002;75:453‐467.
    1. Ginde SR, Geliebter A, Rubiano F, et al. Air displacement plethysmography: validation in overweight and obese subjects. Obes Res. 2005;13:1232‐1237.
    1. Siri W. Body composition from fluid space and density In: Brozek J, Hanschel A, eds. Techniques for Measuring Body Composition. Washington, DC: National Academy of Science; 1961;223‐224.
    1. Hall KD, Sacks G, Chandramohan D, et al. Quantification of the effect of energy imbalance on bodyweight. Lancet. 2011;378:826‐837.
    1. Thomas DM, Martin CK, Lettieri S, et al. Can a weight loss of one pound a week be achieved with a 3500‐kcal deficit? Commentary on a commonly accepted rule. Int J Obes (Lond). 2013;37:1611‐1613.
    1. Sumithran P, Prendergast LA, Delbridge E, et al. Long‐term persistence of hormonal adaptations to weight loss. N Engl J Med. 2011;365:1597‐1604.
    1. Rolin B, Larsen MO, Christoffersen BO, Lau J, Knudsen LB. In vivo effect of semaglutide in pigs supports its potential as a long‐acting GLP‐1 analogue for once‐weekly dosing. Diabetes. 2015;64(suppl 1):1119.
    1. Edwards CM, Stanley SA, Davis R, et al. Exendin‐4 reduces fasting and postprandial glucose and decreases energy intake in healthy volunteers. Am J Physiol Endocrinol Metab. 2001;281:E155‐E161.
    1. Horowitz M, Flint A, Jones KL, et al. Effect of the once‐daily human GLP‐1 analogue liraglutide on appetite, energy intake, energy expenditure and gastric emptying in type 2 diabetes. Diabetes Res Clin Pract. 2012;97:258‐266.
    1. Marso SP, Bain SC, Consoli A, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016;375:1834‐44.

Source: PubMed

Спонсоры и соавторы

Заболевания

Медикаментозные вмешательства

Подписаться